TY - JOUR
T1 - Outcomes of sorafenib treatment of advanced renal cell carcinoma according to IMDC risk criteria
T2 - analysis of Japanese real-world data from postmarketing all-patient surveillance of sorafenib
AU - Inamoto, Teruo
AU - Azuma, Haruhito
AU - Adachi, Masatoshi
AU - Okayama, Yutaka
AU - Sunaya, Toshiyuki
AU - Oya, Mototsugu
N1 - Funding Information:
Under the guidance of the authors, professional medical writing support was provided by DP Figgitt, Content Ed Net, with funding from Bayer Yakuhin Ltd.
Publisher Copyright:
© 2022 Future Medicine Ltd.
PY - 2022/4
Y1 - 2022/4
N2 - Aim: To assess sorafenib survival outcomes in renal cell carcinoma patients using standard International Metastatic Renal Cell Carcinoma Data Consortium (IMDC) risk criteria. Patients & methods: The authors restratified a real-world cohort of 3255 advanced renal cell carcinoma patients, obtained from Japanese sorafenib postmarketing surveillance, to assess survival outcomes using IMDC criteria; intermediate risk was subdivided into intermediate 1 (Int-1) and imterdemiate 2 (Int-2; one and two risk factors, respectively). Results: Overall, 2225 (68%) IMDC-evaluable patients were reclassified as favorable (17%), intermediate (62%) and poor (21%) risk, with median progression-free survival of 10.4, 8.1 and 3.4 months, respectively. Int-1 (36%) and Int-2 (26%) subgroups had median progression-free survival of 10.1 and 6.0 months, respectively. Sorafenib had acceptable safety/tolerability. Conclusion: Sorafenib effectiveness was promising for IMDC intermediate risk, particularly Int-1, warranting further investigation.
AB - Aim: To assess sorafenib survival outcomes in renal cell carcinoma patients using standard International Metastatic Renal Cell Carcinoma Data Consortium (IMDC) risk criteria. Patients & methods: The authors restratified a real-world cohort of 3255 advanced renal cell carcinoma patients, obtained from Japanese sorafenib postmarketing surveillance, to assess survival outcomes using IMDC criteria; intermediate risk was subdivided into intermediate 1 (Int-1) and imterdemiate 2 (Int-2; one and two risk factors, respectively). Results: Overall, 2225 (68%) IMDC-evaluable patients were reclassified as favorable (17%), intermediate (62%) and poor (21%) risk, with median progression-free survival of 10.4, 8.1 and 3.4 months, respectively. Int-1 (36%) and Int-2 (26%) subgroups had median progression-free survival of 10.1 and 6.0 months, respectively. Sorafenib had acceptable safety/tolerability. Conclusion: Sorafenib effectiveness was promising for IMDC intermediate risk, particularly Int-1, warranting further investigation.
KW - Intermediate risk
KW - Kidney cancer
KW - Risk stratification
KW - Targeted therapy
KW - Tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=85127936362&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127936362&partnerID=8YFLogxK
U2 - 10.2217/fon-2021-1001
DO - 10.2217/fon-2021-1001
M3 - Article
C2 - 35023360
AN - SCOPUS:85127936362
SN - 1479-6694
VL - 18
SP - 1371
EP - 1380
JO - Future Oncology
JF - Future Oncology
IS - 11
ER -
